FINWIRES · TerminalLIVE
FINWIRES

$DYN

10 stories mentioning DYNUpdated 5d ago

Every FINWIRES story that references DYN, newest first.

Wire

Dyne Therapeutics Receives FDA Clearance to Start Trial of Muscle Disease Treatment

Dyne Therapeutics (DYN) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for DYNE-302, allowing the company to begin a Phase 1 trial in patients with facioscapulohumeral muscular dystrophy.The randomized, placebo-controlled, double-blind, multiple ascending-dose Phase 1 trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DYNE-302 in ambulatory adults with FSHD, including biomarkers of DUX4 activity, the company said.Dyne said DYNE-302 is its third clinical-stage program based on its FORCE platform and plans to pursue a traditional US approval pathway for the therapy.Dyne Therapeutics shares were up 1% in premarket trading.

$DYN
Research

Cantor Fitzgerald Initiates Coverage on Dyne Therapeutics With Overweight Rating

$DYN
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively traded Invesco QQQ Trust (QQQ) was down 1% in Wednesday's premarket activity, as investors awaited results from major technology companies.US stock futures were also lower, with S&P 500 Index futures up 0.4%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures retreating 0.9% before the start of regular trading.Mortgage applications rose by 1.9% in the week ended July 17 despite an increase in 30-year fixed mortgage rates, according to Mortgage Bankers Association data released Wednesday.The weekly petroleum stocks data will be released at 10:30 am ET.In premarket action, bitcoin was down by 0.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.7% lower, Ether ETF (EETH) advanced 0.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) was up 1.3%, while the iShares US Healthcare ETF (IYH) slipped 0.6%. The iShares Biotechnology ETF (IBB) was 0.5% lower.Dyne Therapeutics (DYN) stock was down more than 8% premarket after the company priced an upsized secondary public offering of 18.3 million shares at $20.50 each.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.7%, the Vanguard Industrials Index Fund (VIS) lost 0.01%, and the iShares US Industrials ETF (IYJ) was 0.5% higher.GE Vernova (GEV) stock was down more than 1% before the opening bell after the company reported lower-than-expected Q2 earnings.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.5%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat, and the iShares US Consumer Staples ETF (IYK) was down 0.7%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.6% higher.Cal-Maine Foods (CALM) shares were down more than 4% pre-bell after the company swung to a fiscal Q4 loss.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.04%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.Banco Santander (SAN) shares traded up 1% in early-hours activity after the company reported higher Q2 earnings and revenue.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 1.3%, the iShares US Technology ETF (IYW) was 0.2% lower, and the iShares Expanded Tech Sector ETF (IGM) was up 0.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) fell by 1.8%, while the iShares Semiconductor ETF (SOXX) was down 2.8%.Nvidia (NVDA) shares were down more than 1% in premarket activity after gaining nearly 2% at the prior close. Chief Executive Jensen Huang is expected to meet Samsung Electronics Chairman Jay Lee, SK Group Chairman Chey Tae-won and Naver founder Lee Hae-jin in the US this week for an artificial intelligence roundtable, according to news reports.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.1%.Shell (SHEL) stock was up more than 1% before market open following a 1.2% gain in the previous session. The company resumed operations at a 200,000-barrel-per-day crude oil unit at its Pernis oil refinery in the Netherlands on Monday following a brief disruption, Reuters reported Tuesday.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 3.4% to $87.24 per barrel on the New York Mercantile Exchange. Natural gas was up by 1.7% to $2.91 per 1 million British Thermal Units. The United States Oil Fund (USO) was up 2.8%, while the United States Natural Gas Fund (UNG) was 1.1% higher.Gold futures for July advanced 1.3% to $4,128.70 an ounce on the Comex. Silver futures were up 0.9% to $59.64 an ounce. SPDR Gold Shares (GLD) increased 1.1%, and the iShares Silver Trust (SLV) was 1.4% higher.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CALM$DYN$EEM$EETH$EXI$FAS$FAZ$GEV$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NVDA$PMR$QQQ$RTH$SAN$SHEL$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Flat to Lower Premarket Monday

Healthcare stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.Tempus AI (TEM) agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $1.5 billion. Shares of Tempus AI were down more than 4% and Personalis stock fell past 5% pre-bell.Dyne Therapeutics (DYN) stock was up more than 4% after the company said the US Food and Drug Administration accepted its biologics license application for z-rostudirsen to treat Duchenne muscular dystrophy patients amenable to exon 51 skipping.Kamada (KMDA) shares were up more than 4% after the company said it has signed a three-year $50 million agreement to supply plasma to an unnamed biopharmaceutical company focused on plasma-derived therapies.

$DYN$IBB$KMDA$PSNL$TEM$XLV
Insider Trading

Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing

Jason P Rhodes, Director, on June 23, 2026, sold 267,760 shares in Dyne Therapeutics (DYN) for $5,646,497. Following the Form 4 filing with the SEC, Rhodes has control over a total of 1,089,006 common shares of the company, with 1,089,006 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/xslF345X05/form4-06262026_120619.xmlPrice: $21.20, Change: $+0.59, Percent Change: +2.86%

$DYN
Research

TD Cowen Initiates Dyne Therapeutics at Buy

Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $38.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$DYN
Insider Trading

Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing

Dirk Kersten, Director, on June 22, 2026, sold 263,962 shares in Dyne Therapeutics (DYN) for $5,464,611. Following the Form 4 filing with the SEC, Kersten has control over a total of 3,848,256 common shares of the company, with 3,848,256 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/xslF345X05/ownership.xml

$DYN
Wire

Dyne Can Unlock Value in Two Drug Prospects, RBC Says

Dyne Therapeutics (DYN) reiterated its confidence in upcoming biologics license application submission for Duchenne muscular dystrophy in Q2, RBC Capital Markets said in a Monday report.The report said an accelerated approval is possible in early 2027, assuming priority review, and noted that a confirmatory trial to show functional benefit is being planned.The note also said the firm has reached its target participants in ACHIEVE study for myotonic dystrophy type 1, but will enroll additional patients, with expected readout in early 2027."Overall, we would remain buyers given a platform that can unlock value in muscle, two relatively de-risked drugs (DMD and DM1)," the report said.The note also said the stock continues to trade at a fraction of the $12 billion Novartis (NVS) was willing to pay for RNA therapeutics with Avidity Biosciences acquisition.RBC assigned an outperform, speculative risk rating, and a $30 price target.Price: $17.90, Change: $-0.56, Percent Change: -3.03%

$DYN
Insider Trading

Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing

Jason P Rhodes, Director, on April 23, 2026, sold 384,549 shares in Dyne Therapeutics (DYN) for $7,101,120. Following the Form 4 filing with the SEC, Rhodes has control over a total of 1,206,026 common shares of the company, with 1,206,026 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/xslF345X05/form4-04272026_100429.xml

$DYN
Insider Trading

Dyne Therapeutics Insider Sold Shares Worth $16,477,388, According to a Recent SEC Filing

Jason P Rhodes, Director, on April 20, 2026, sold 834,302 shares in Dyne Therapeutics (DYN) for $16,477,388. Following the Form 4 filing with the SEC, Rhodes has control over a total of 8,296,163 common shares of the company, with 8,296,163 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1818794/000157701426000002/xslF345X05/form4-04222026_100417.xml

$DYN

Track with the FINWIRES app suite